English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/216654
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Can activation of NRF2 be a strategy against COVID-19?

AuthorsCuadrado, Antonio ; Pajares, Marta; Benito, Cristina; Jiménez-Villegas, José; Escoll, Maribel; Fernández-Ginés, Raquel; García-Yagüe, Ángel Juan; Lastra, Diego; Manda, Gina; Rojo, Ana I. ; Dinkova-Kostova, Albena T.
KeywordsAnti-inflammatory
ARDS
Bardoxolone methyl
KEAP1
SARS-CoV-2
Sulforaphane
Issue Date14-Jul-2020
PublisherElsevier
CitationTrends in Pharmacological Sciences 41(9): 598-610 (2020)
AbstractAcute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated pro-inflammatory cytokines release (cytokine storm) and loss of T-lymphocytes (leucopenia) characterize the most aggressive presentation. Here we propose that a multi-faceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2), can be deployed against the virus. The strategy provides robust cytoprotection by restoring the redox and protein homeostasis, promoting resolution of inflammation, and facilitating repair. NRF2 activators such as sulforaphane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well-documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19.
Publisher version (URL)https://doi.org/10.1016/j.tips.2020.07.003
URIhttp://hdl.handle.net/10261/216654
DOIhttp://dx.doi.org/10.1016/j.tips.2020.07.003
ISSN0165-6147
E-ISSN1873-3735
Appears in Collections:(IIBM) Artículos
(VICYT) Colección Especial COVID-19
Files in This Item:
File Description SizeFormat 
cancov19.pdf2,02 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.